Contrasting Eisai (ESALY) and KERRY Grp PLC/S (KRYAY)

Eisai (OTCMKTS:ESALY) and KERRY Grp PLC/S (OTCMKTS:KRYAY) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Dividends

Eisai pays an annual dividend of $0.62 per share and has a dividend yield of 0.7%. KERRY Grp PLC/S pays an annual dividend of $0.78 per share and has a dividend yield of 0.7%. Eisai pays out 38.0% of its earnings in the form of a dividend.

Profitability

This table compares Eisai and KERRY Grp PLC/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eisai 8.93% 8.94% 5.23%
KERRY Grp PLC/S N/A N/A N/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Eisai and KERRY Grp PLC/S, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eisai 0 0 0 0 N/A
KERRY Grp PLC/S 0 0 0 0 N/A

Institutional & Insider Ownership

0.1% of Eisai shares are owned by institutional investors. Comparatively, 0.1% of KERRY Grp PLC/S shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Eisai has a beta of -0.21, meaning that its share price is 121% less volatile than the S&P 500. Comparatively, KERRY Grp PLC/S has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.

Earnings and Valuation

This table compares Eisai and KERRY Grp PLC/S’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eisai $5.42 billion 5.00 $466.60 million $1.63 56.03
KERRY Grp PLC/S $7.24 billion 2.65 $665.18 million N/A N/A

KERRY Grp PLC/S has higher revenue and earnings than Eisai.

Summary

KERRY Grp PLC/S beats Eisai on 5 of the 9 factors compared between the two stocks.

About Eisai

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals worldwide. It offers Halaven and Lenvima, an anticancer agent; Aloxi, an antiemetic agent; Aricept, a treatment for Alzheimer's disease; Fycompa, an antiepileptic agent; Methycobal for peripheral neuropathy treatment; BELVIQ for anti-obesity treatment; and LYRICA for neuropathic pain treatment. The company also provides Lunesta, a non-benzodiazepine hypnotic agent for insomnia treatment; Pariet, a proton pump inhibitor; HUMIRA, a human anti-TNF-a monoclonal antibody; and epilepsy franchise products, including Zonegran, Zebinix, Fycompa, and Inovelo, which are antiepileptic agents. In addition, it offers Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome; Actonel, an osteoporosis treatment; and Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment. The company has strategic partnerships with Quintiles Inc. for developing six types of anticancer compound candidates; and Epizyme, Inc. to discover, develop, and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically defined patients. It also has collaboration agreement with Ono Pharmaceutical Co., Ltd. to develop Lenvima (lenvatinib mesylate), a multi-kinase inhibitor, as well as Opdivo, a human anti-human programmed cell death-1 monoclonal antibody, for the treatment of hepatocellular carcinoma; and Merck & Co., Inc. to develop and commercialize Lenvima. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

About KERRY Grp PLC/S

Kerry Group plc, together with its subsidiaries, develops, manufactures, and delivers technology based taste and nutrition solutions for the food, beverage, and pharmaceutical industries in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company operates in two segments, Taste & Nutrition and Consumer Foods. The Taste & Nutrition segment manufactures and distributes a portfolio of functional ingredients and actives; and offers taste and nutrition technologies, systems, and solutions. The Consumer Foods segment manufactures and supplies added value branded and consumer branded chilled foods primarily to the Irish and the United Kingdom markets. This segment offers meat and savory products, dairy products, and meal solutions for retailers, convenience stores, and e-commerce channels under the LowLow, Cheestrings, Dairygold, Charleville, Denny, Galtee, Richmond, Wall's, Mattessons, Fire & Smoke, and Yollies brand names. It also produces retail private label products, such as chilled and frozen ready meals, cooked meats, and cheese and dairy products. In addition, the company is involved in the agri business. Kerry Group plc was founded in 1972 and is headquartered in Tralee, Ireland.

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply